DK0470184T3 - Specifikke antistoffer for det CD4-bindende domæne i HIV - Google Patents

Specifikke antistoffer for det CD4-bindende domæne i HIV

Info

Publication number
DK0470184T3
DK0470184T3 DK90907850.3T DK90907850T DK0470184T3 DK 0470184 T3 DK0470184 T3 DK 0470184T3 DK 90907850 T DK90907850 T DK 90907850T DK 0470184 T3 DK0470184 T3 DK 0470184T3
Authority
DK
Denmark
Prior art keywords
hiv
binding domain
specific antibodies
epitope
antibody
Prior art date
Application number
DK90907850.3T
Other languages
English (en)
Inventor
Nancy T Chang
Cecily Rou-Yun Sun
Michael Sek C Fung
Tse-Wen Chang
William Nai-Chau Sun
Original Assignee
Tanox Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Biosystems Inc filed Critical Tanox Biosystems Inc
Application granted granted Critical
Publication of DK0470184T3 publication Critical patent/DK0470184T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK90907850.3T 1989-04-25 1990-04-25 Specifikke antistoffer for det CD4-bindende domæne i HIV DK0470184T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34295089A 1989-04-25 1989-04-25

Publications (1)

Publication Number Publication Date
DK0470184T3 true DK0470184T3 (da) 1997-03-10

Family

ID=23344000

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90907850.3T DK0470184T3 (da) 1989-04-25 1990-04-25 Specifikke antistoffer for det CD4-bindende domæne i HIV

Country Status (9)

Country Link
EP (1) EP0470184B1 (da)
JP (1) JPH0768276B2 (da)
AT (1) ATE148918T1 (da)
AU (1) AU633570B2 (da)
CA (1) CA2051107A1 (da)
DE (1) DE69029937T2 (da)
DK (1) DK0470184T3 (da)
ES (1) ES2097759T3 (da)
WO (1) WO1990012868A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
EP0511308B2 (en) * 1989-12-27 2003-07-09 Centocor, Inc. Chimeric immunoglobulin for cd4 receptors
WO1991012021A2 (en) * 1990-02-13 1991-08-22 Oxford Virology Plc Therapeutic agents, and intermediates for the synthesis thereof
AP237A (en) * 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
JPH05262662A (ja) * 1991-07-15 1993-10-12 Calpis Food Ind Co Ltd:The Ｈｉｖ重感染防止剤、抗イディオタイプ抗体作製用抗原及び抗イディオタイプ抗体の製造法
US5558865A (en) * 1991-08-22 1996-09-24 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
JPH07504571A (ja) * 1992-03-06 1995-05-25 クリージエン・インコーポレーテツド 病原体−標的生物触媒
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
ATE177843T1 (de) * 1994-01-19 1999-04-15 Us Health Peptomere mit erhöhter immunogenizität
US5618922A (en) 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
JP2933159B2 (ja) * 1996-03-18 1999-08-09 株式会社椿本チエイン 直線作動機のリミットスイッチ取付構造
CA2441287C (en) 2001-03-22 2014-06-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
JP2014502262A (ja) * 2010-11-12 2014-01-30 ザ ロックフェラー ユニバーシティ Ｈｉｖ治療用の融合タンパク質

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007616A1 (en) * 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
EP0279688B1 (en) * 1987-02-20 1997-04-16 Genentech, Inc. Methods and compositions for the use of HIV env polypeptides and antibodies thereto
JP2520464B2 (ja) * 1987-05-29 1996-07-31 タノツクス・バイオシステムズ・インコーポレーテツド Ｈｉｖ―１を中和するモノクロ―ナル抗体
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
AU6523590A (en) * 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use

Also Published As

Publication number Publication date
JPH0768276B2 (ja) 1995-07-26
JPH04506004A (ja) 1992-10-22
ES2097759T3 (es) 1997-04-16
CA2051107A1 (en) 1990-10-26
WO1990012868A1 (en) 1990-11-01
AU633570B2 (en) 1993-02-04
AU5553690A (en) 1990-11-16
EP0470184A4 (en) 1992-10-07
ATE148918T1 (de) 1997-02-15
DE69029937D1 (de) 1997-03-27
DE69029937T2 (de) 1997-05-28
EP0470184B1 (en) 1997-02-12
EP0470184A1 (en) 1992-02-12

Similar Documents

Publication Publication Date Title
DK0470184T3 (da) Specifikke antistoffer for det CD4-bindende domæne i HIV
BR9305435A (pt) Processo para determinação de peptídeos correspondendo a epítopos imunologicamente importantes e seu uso em um processo para determinação de anticorpos ou peptídeos biotinilados correspondendo a epítopos imunologicamente importantes, processo para preparação dos mesmos e composições contendo os mesmos
BR0210598A (pt) Complexo solúvel que compreende uma glicoproteìna retroviral de superfìcie
WO2002064615A3 (en) Monoclonal antibodies to human immunodeficiency virus and uses thereof
SE9102975L (sv) Bakterofag och vaerd till anvaendning foer framstaellning av hiv-proteiner och peptider
PT1159298E (pt) Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv
EP1878742A3 (en) HIV peptides, antigens, vaccine compositions, immunoassay and a method of detecting antibodies induced by HIV
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
DE69013950D1 (de) Monoklonaler Antikörper zur Unterscheidung HIV-2-seropositiver von HIV-1-seropositiven Individuen.
SE9000333D0 (sv) Monoklonal antikropp
KR930702509A (ko) 사람 면역결핍 바이러스(hiv)면역치료제
DE69128108D1 (de) Monoklonaler Antikörper gegen HTLV-III (Stamm MN)
PT690725E (pt) Metodos para inibicao de doenca associada a vih que utilizam anticorpos monoclonais dirigidos contra celulas t citotoxicas anti-proprio
NO175846C (no) Fremgangsmåte for å oppnå et immunogen
ES2195200T3 (es) Construccion de peptidos de rama multiples.
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
SE8701765D0 (sv) Analysis method and means therefor
CA2160696A1 (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
DK0569428T3 (da) Fremgangsmåde til diagnosticering in vitro af HIV-1-virusinfektioner
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
WO1999045969A3 (de) Radioimmunpharmakon zur behandlung der hiv-1-infektion
AU7664194A (en) Use of antibodies against beta -2 microglobulin-free, class i hla molecules to provide hiv diagnostic tests as well as compositions having a protective action against hiv infections
DE3777196D1 (de) Anti-parathyroid-antikoerper-praeparat.
SU1540269A1 (ru) Штамм гибридных культивируемых клеток животного mus musculus, используемый для получения моноклональных антител к поверхностному гликопротеину вирусов комплекса клещевого энцефалита